Cargando…
Understanding and Managing Corticosteroid-Induced Osteoporosis
Glucocorticoids are effective immunosuppressants used in a wide variety of diseases. Their use results in secondary osteoporosis in about 30–50% of chronic glucocorticoid users. Glucocorticoids cause a rapid decline in bone strength within the first 3–6 months mostly due to increased bone resorption...
Autores principales: | Kobza, Alexandra O, Herman, Deena, Papaioannou, Alexandra, Lau, Arthur N, Adachi, Jonathan D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259736/ https://www.ncbi.nlm.nih.gov/pubmed/34239333 http://dx.doi.org/10.2147/OARRR.S282606 |
Ejemplares similares
-
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010) -
An overview of osteoporosis and frailty in the elderly
por: Li, Guowei, et al.
Publicado: (2017) -
Improvement in health-related quality of life in osteoporosis patients treated with teriparatide
por: Lau, Arthur N, et al.
Publicado: (2008) -
The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer
por: Al-Shamsi, Humaid O., et al.
Publicado: (2012) -
Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”
por: Al-Shamsi, Humaid O., et al.
Publicado: (2017)